Nonamyloid PET Biomarkers and Alzheimer's Disease: Current and Future Perspectives

Lucas Porcello Schilling; Antoine Leuzy; Eduardo Rigon Zimmer; Serge Gauthier; Pedro Rosa-Neto


Future Neurology. 2014;9(6):597-613. 

In This Article

Future Perspective

On the basis of recent biomarker studies, AD pathophysiology is thought to precede the onset of clinical symptoms by up to a decade or more. As such the field has begun to shift toward the early diagnosis of AD, recognizing that a relatively broad window of opportunity exists, potentially, for intervention with novel disease modifying therapies. Though none have yet to demonstrate efficacy in Phase III studies, various strategies targeting primarily amyloid and tau are under development. As such, multitracer approaches utilizing, for instance, [18F]FDG and tau ligands, will be required in both symptomatic and disease-modifying trials in order to determine tau engagement and treatment response. Similarly, neuroinflammatory molecular imaging can similarly contribute to anti-inflammatory interventions. Finally, on the basis of the vast literature reporting the effects of psychiatric drug, tracers for neurotransmission may contribute to the development of improved therapeutic prospects addressing neuropsychiatric features in AD as well as the refinement of current treatment protocols and improved study designs.